carbamates has been researched along with Bilirubinemia in 5 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hepatic decompensation is a severe on-treatment adverse event for chronic hepatitis C treated with paritaprevir/ritonavir/ombitasvir and dasabuvir (PrOD)." | 7.88 | Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis. ( Chen, WT; Chen, YC; Hsieh, YC; Huang, CH; Jeng, WJ; Lin, CY; Lin, SM; Sheen, IS; Tai, DI; Teng, W, 2018) |
| " Transient benign unconjugated hyperbilirubinemia has been observed clinically with several drugs including indinavir, cyclosporine, and rifamycin SV." | 7.80 | In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia. ( Bow, DA; Chiou, WJ; de Morais, SM; Kikuchi, R; Li, X; Voorman, RL, 2014) |
| "Hepatic decompensation is a severe on-treatment adverse event for chronic hepatitis C treated with paritaprevir/ritonavir/ombitasvir and dasabuvir (PrOD)." | 3.88 | Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis. ( Chen, WT; Chen, YC; Hsieh, YC; Huang, CH; Jeng, WJ; Lin, CY; Lin, SM; Sheen, IS; Tai, DI; Teng, W, 2018) |
| "The combination of ombitasvir, dasabuvir, and paritaprevir/ritonavir (considered as the 3D regimen) has proven to be associated with high sustained virologic response and optimal tolerability in hepatitis C virus-infected patients." | 3.83 | Severe Hyperbilirubinemia in an HIV-HCV-Coinfected Patient Starting the 3D Regimen That Resolved After TDM-Guided Atazanavir Dose Reduction. ( Cattaneo, D; Clementi, E; Gervasoni, C; Milazzo, L; Riva, A, 2016) |
| " Transient benign unconjugated hyperbilirubinemia has been observed clinically with several drugs including indinavir, cyclosporine, and rifamycin SV." | 3.80 | In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia. ( Bow, DA; Chiou, WJ; de Morais, SM; Kikuchi, R; Li, X; Voorman, RL, 2014) |
| "Hepatic decompensation and acute liver failure are rare but severe complications of Ritonavir-boosted Paritaprevir, Ombitasvir and Dasabuvir plus Ribavirin therapy in patients with compensated cirrhosis." | 1.43 | A Case of Acute Liver Failure during Ritonavir-Boosted Paritaprevir, Ombitasvir and Dasabuvir Therapy in a Patient with HCV Genotype 1b Cirrhosis. ( Andreone, P; Magalotti, D; Martino, E; Masetti, M; Scuteri, A; Zoli, M, 2016) |
| " Modification of the core regiochemistry and stereochemistry significantly affected the potency, metabolic stability, and oral bioavailability of the inhibitors, as did the variation of a pendent arylmethyl P3 group." | 1.35 | 2-Pyridyl P1'-substituted symmetry-based human immunodeficiency virus protease inhibitors (A-792611 and A-790742) with potential for convenient dosing and reduced side effects. ( Chen, HJ; Colletti, L; Degoey, DA; Dekhtyar, T; Flentge, CA; Flosi, WJ; Grampovnik, DJ; Kati, WM; Kempf, DJ; Klein, LL; Mamo, M; Marsh, KC; Mo, H; Molla, A; Morfitt, DC; Nguyen, B; Randolph, JT; Schmidt, JM; Stoll, V; Swanson, SJ; Yeung, CM, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hsieh, YC | 1 |
| Jeng, WJ | 1 |
| Huang, CH | 1 |
| Teng, W | 1 |
| Chen, WT | 1 |
| Chen, YC | 1 |
| Lin, SM | 1 |
| Tai, DI | 1 |
| Lin, CY | 1 |
| Sheen, IS | 1 |
| Chiou, WJ | 1 |
| de Morais, SM | 1 |
| Kikuchi, R | 1 |
| Voorman, RL | 1 |
| Li, X | 1 |
| Bow, DA | 1 |
| Cattaneo, D | 1 |
| Riva, A | 1 |
| Clementi, E | 1 |
| Milazzo, L | 1 |
| Gervasoni, C | 1 |
| Masetti, M | 1 |
| Magalotti, D | 1 |
| Martino, E | 1 |
| Andreone, P | 1 |
| Scuteri, A | 1 |
| Zoli, M | 1 |
| Degoey, DA | 1 |
| Grampovnik, DJ | 1 |
| Flentge, CA | 1 |
| Flosi, WJ | 1 |
| Chen, HJ | 1 |
| Yeung, CM | 1 |
| Randolph, JT | 1 |
| Klein, LL | 1 |
| Dekhtyar, T | 1 |
| Colletti, L | 1 |
| Marsh, KC | 1 |
| Stoll, V | 1 |
| Mamo, M | 1 |
| Morfitt, DC | 1 |
| Nguyen, B | 1 |
| Schmidt, JM | 1 |
| Swanson, SJ | 1 |
| Mo, H | 1 |
| Kati, WM | 1 |
| Molla, A | 1 |
| Kempf, DJ | 1 |
5 other studies available for carbamates and Bilirubinemia
| Article | Year |
|---|---|
Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis.
Topics: 2-Naphthylamine; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cohort Studies; Cy | 2018 |
In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia.
Topics: Antirheumatic Agents; Atazanavir Sulfate; Bilirubin; Carbamates; Cyclosporine; Furans; Glucuronosylt | 2014 |
Severe Hyperbilirubinemia in an HIV-HCV-Coinfected Patient Starting the 3D Regimen That Resolved After TDM-Guided Atazanavir Dose Reduction.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Atazanavir Sulfate; Carbamates; Coinfection; Cyclopropa | 2016 |
A Case of Acute Liver Failure during Ritonavir-Boosted Paritaprevir, Ombitasvir and Dasabuvir Therapy in a Patient with HCV Genotype 1b Cirrhosis.
Topics: 2-Naphthylamine; Aged, 80 and over; Anilides; Antiviral Agents; Ascites; Carbamates; Chemical and Dr | 2016 |
2-Pyridyl P1'-substituted symmetry-based human immunodeficiency virus protease inhibitors (A-792611 and A-790742) with potential for convenient dosing and reduced side effects.
Topics: Animals; Binding Sites; Biological Availability; Caco-2 Cells; Carbamates; Cell Membrane Permeabilit | 2009 |